Evaluation of Retina in Patients With Glaucoma Using Topical Prostaglandins Undergoing Trabeculectomy Surgery - Trial NCT06000280
Access comprehensive clinical trial information for NCT06000280 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidade Federal de Goias and is currently Completed. The study focuses on Glaucoma. Target enrollment is 37 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universidade Federal de Goias
Timeline & Enrollment
N/A
Jan 04, 2021
Mar 31, 2023
Primary Outcome
Previous use of prostaglandins does not change macular thickness after trabeculectomy
Summary
The aim of this study was to verify whether prostaglandin analogue (PA) eye drops influence
 the retinal thickness of glaucomatous patients undergoing trabeculectomy (TRAB) surgery. We
 selected eyes of patients with glaucoma with surgical indication for TRAB who were using PA
 eye drops and without previous retinal alterations, from the Centro de Referência em
 Oftalmologia (CEROF) from the Federal University of Goiás and Fundação Banco de Olhos de
 Goiás (FUBOG). Patients were divided into 2 groups: the study group (SG) and the control
 group (CG). In the CG, the PA was suspended between 30 and 60 days before the preoperative
 exams were performed (maximum of 15 days before surgery for both groups). All patients
 included were submitted to various eye exams before the procedure, and postoperatively on 3
 occasions: 1 to 3 days (PO1), 6 to 9 days (PO7) and 27 to 30 days (PO30) after surgery.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06000280
Non-Device Trial